Effectiveness and safety of rituximab-pvvr versus originator rituximab for rheumatoid arthritis in the veterans health administration
Clicks: 1
ID: 324379
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #189 of 200 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 200 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVE: Real-world comparisons of rituximab biosimilars with originator rituximab have largely focused on oncology, with limited evidence in rheumatoid arthritis (RA). This gap is particularly pertinent to the Veterans Health Administration (VHA), where patients with RA are older and have greater comorbidity. We evaluated the effectiveness and safety of rituximab-pvvr versus originator rituximab in Veterans with RA by (1) describing treatment patterns, (2) assessing effectiveness, (3) evaluating adverse events, and (4) identifying reasons for switching back to the originator after initiating the biosimilar. METHODS: We conducted a retrospective cohort study using VHA Pharmacy Benefits Management data among Veterans aged ≥18 years who received originator rituximab or rituximab-pvvr for RA between March 1, 2020 and August 31, 2023. Effectiveness outcomes (e.g., prednisone use) and safety outcomes (e.g., infection) were assessed using regression analyses within entropy-balanced subgroups of incident originator and biosimilar users. RESULTS: A total of 1,717 Veterans with RA received originator rituximab or rituximab-pvvr during the study period. Among 1,074 incident users, there were no significant differences between originator and biosimilar groups in effectiveness (e.g., discontinued prednisone use: Risk Difference (RD) = 0.05; 95% Confidence Interval (CI), -0.04 to 0.14) or safety (e.g., infection-related hospitalizations or emergency department visits: RD = -0.02; 95% CI, -0.08 to 0.05). CONCLUSIONS: We found no clinically meaningful differences in the effectiveness or safety of rituximab-pvvr compared with originator rituximab among incident users with RA. These real-world findings support the clinical use of rituximab-pvvr and may improve clinician and patient confidence in biosimilar adoption.
| Reference Key |
openalex_W7201980987
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Samaneh Ghassemi, Jasvinder A Singh, Rong Jiang, Yinong Young‐Xu, Francesca Cunningham, Peter A Glassman, Xinhua Zhao, Cedric Salone, Anthony Au, Donald R Miller, Qoua Her, Diane Dong, Sherrie L. Aspinall |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag406
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.